Description: Janssen Pharmaceuticals, Inc., is pleased to announce changes to RISPERDAL CONSTA® (risperidone) LONG-ACTING INJECTION Dose Packs
bipolar disorder (180) bipolar i disorder (9) risperidone (5) bipolar i (2) bipolar 1 (2) risperdal consta (1)
Approved for the treatment of Schizophrenia and for the maintenance treatment of Bipolar I Disorder
Helping to provide predictability* † for more of your adult patients with Bipolar I Disorder when administered every 2 weeks. 1
The most common adverse reaction in clinical trials in patients with bipolar disorder was weight increase (5% in monotherapy trial). 1